Treatment for locally-advanced gastric cancer: current status and perspectives

Gastric cancer takes 2 nd place in the structure of mortality from cancer. The proportion of patients with initially locally advanced inoperable gastric cancer (LAIGC) is up to 30%. Only 25-40% of patients with localized adenocarcinoma of the stomach may be candidates for potentially curative surgical treatment. So far, there is no established standard in the treatment of such patients. All treatments can be divided into: 1) aimed at prolonging life (chemotherapy (CT), targeted therapy (TT), radiation therapy (RT)), and 2) to handle the symptoms (CT, RT, palliative surgery, laser destruction, photodynamic therapy, argon coagulation, etc.). The present review focuses on modern methods of treatment for the LAIGC based on the evidence obtained from randomized controlled trials and metaanalyses. Perspectives of CT, TT, RT in locally-advanced inoperable gastric cancer and implementation of new technologies are also discussed.